课题基金 / 基金详情

Characterization of novel viral sensitizers that enhance oncolytic herpes simplex-1 virus (HSV1) and vesicular stomatitis virus (VSV) infection in cancer cells through polo-like kinase-1(PLK1) inhibition

Characterization of novel viral sensitizers that enhance oncolytic herpes simplex-1 virus (HSV1) and vesicular stomatitis virus (VSV) infection in cancer cells through polo-like kinase-1(PLK1) inhibition
通过抑制 Polo 样激酶 1 (PLK1) 增强癌细胞中溶瘤单纯疱疹病毒 (HSV1) 和水疱性口炎病毒 (VSV) 感染的新型病毒敏化剂的特性
批准号：
428819
负责人：
Gilchrist Victoria
金额：
$1.27万
依托单位：
University of Ottawa
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-12-01 至 2020-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=428819&lang=en
关键词：
Glioblastoma Herpes Simplex Virus 1 (Hsv1) Kinase Inhibitors Oncolytic Virus Polo-Like Kinase 1 (Plk1) Vesicular Stomatitis Virus (Vsv) Viral Sensitizer

项目摘要

项目成果

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
"The oncolytic herpes simplex virus 1 (oHSV1) is FDA-approved for the treatment of advanced melanoma, while rhabdoviruses (e.g. Vesicular Stomatitis Virus (oVSV)) are undergoing clinical investigation. OVs are genetically engineered to enhance tumour trop
期刊论文(0)
专著(0)
科研奖励(0)
会议论文